GEN-1013

GEN-1013 is a preclinical gene therapy developed by GenVivo for the treatment of solid tumors. It utilizes a non-replicating mRNA vector platform to deliver a dual payload consisting of an enhanced prodrug-activating enzyme (herpes simplex virus–enhanced thymidine kinase, HSV-eTK) and the immunostimulatory cytokine interleukin-12 (IL-12). The therapy is designed to stimulate potent anti-tumor immune responses by promoting localized IL-12 expression within tumors, thereby enhancing cytolytic activity and tumor infiltration by natural killer (NK) cells and cytotoxic T lymphocytes (CTLs), as well as activating Th1-type immune responses. Preclinical studies have demonstrated significant tumor reduction in murine cancer models with both intravenous and intratumoral administration routes, accompanied by increased interferon-gamma expression in tumor-infiltrating NK and CD8+ T cells. Importantly, delivery was well tolerated with serum IL-12 levels remaining below toxicity thresholds associated with systemic IL-12 therapies[2][4][5][7].